Evaluation of Endoglin (CD105) expression in pediatric rhabdomyosarcoma

Di Paolo, Virginia; Russo, Ida; Boldrini, Renata; Ravà, Lucilla; Pezzullo, Marco; Benedetti, Maria Chiara; Galardi, Angela; Colletti, Marta; Rota, Rossella; Orlando, Domenico; Crocoli, Alessandro; Peinado, Hector; Milano, Giuseppe Maria; Di Giannatale, Angela

doi:10.1186/s12885-017-3947-4

BMC Cancer

Table 1 Characteristics of the 30 patients with Rhabdomyosarcoma

From: Evaluation of Endoglin (CD105) expression in pediatric rhabdomyosarcoma

Pt	Age (mos)	Gender	Histology	Primary site	Primary size (cm)	Metastasis	Nodes	IRS^a Group	COG Risk Groups	EpSSG Risk Groups	Status	CD105/CD31 ratio
1	83	M	ARMS	Extremity	> 5	No	N0	III	Intermediate	HR/G	NED	1.1611
2	65	F	ERMS	Pelvis	> 5	No	N1	III	Intermediate	HR/F	NED	0.6825
3	43	M	ERMS	Abdomen	> 5	No	N0	III	Intermediate	HR/E	NED	0.7466
4	82	F	ARMS	Extremity	> 5	No	N0	III	Intermediate	HR/G	NED	1.0460
5	55	M	ERMS	GU non BP	≤ 5	No	N0	I	Low	LR	NED	1.4292
6	41	M	ERMS	Orbit	> 5	Bone/BM	N0	IV	High	META	DOD	0.5133
7	28	F	ARMS	HN PM	≤ 5	No	N0	II	Intermediate	HR/G	NED	1.4225
8	13	M	ARMS	Orbit	≤ 5	No	N0	III	Intermediate	HR/G	NED	1.7949
9	11	F	ERMS	HN PM	≤ 5	No	N1	III	Intermediate	HR/F	DOD	1.3006
10	37	F	ERMS	GU non BP	≤ 5	No	N0	III	Low	SR/C	NED	0.8942
11	116	F	ERMS	Pelvis	> 5	Lung	Nx	IV	High	META	DOD	1.0158
12	176	M	ARMS	Retroperitoneum	> 5	Lung	N1	IV	High	META	DOD	1.5517
13	48	F	ERMS	GU BP	> 5	No	N0	III	Intermediate	HR/E	NED	1.8627
14	49	F	ARMS	HN PM	> 5	No	N1	III	Intermediate	VERY HR	NED	1.2461
15	17	M	ARMS	HN non PM	≤ 5	No	N0	II	Intermediate	HR/G	NED	1.0354
16	1	M	ERMS	Pelvis	> 5	No	N0	II	Low	HR/E	NED	0.8868
17	1	F	ARMS	HN PM	≤ 5	Multiple^b	N1	IV	High	META	DOD	1.5608
18	16	F	ARMS	Chest wall	≤ 5	No	N0	II	Intermediate	HR/G	NED	0.8651
19	24	M	ARMS	Orbit	≤ 5	No	N0	III	Intermediate	HR/G	DOD	2.0024
20	135	M	ARMS	Chest wall	> 5	No	N1	III	Intermediate	VERY HR	DOD	1.9190
21	26	F	ERMS	Biliary tracts	≤ 5	No	N0	III	Low	SR/D	NED	1.1058
22	97	M	ERMS	Orbit	> 5	No	N0	III	Low	SR/C	NED	1.0274
23	154	M	ERMS	Orbit	> 5	No	N0	II	Low	SR/C	AWD	0.9020
24	14	F	ERMS	Abdomen	> 5	No	N1	I	Low	HR/F	DOD	2.3542
25	23	F	ERMS	Pelvis	> 5	Lung/Bone	N1	IV	High	META	NED	0.7117
26	199	F	ERMS	HN PM	> 5	No	N0	III	Intermediate	HR/E	AWD	0.9333
27	176	M	ARMS	GU non BP	≤ 5	Bone	N1	IV	High	VERY HR	NED	0.5914
28	106	F	ERMS	HN PM	> 5	No	N1	III	Intermediate	HR/F	AWD	1.0217
29	146	M	ERMS	HN non PM	> 5	No	N1	III	Low	HR/F	AWD	0.7733
30	189	M	ERMS	Extremity	> 5	No	N0	III	Intermediate	HR/E	AWD	0.3281

(Pt patient, mos months, M male, F female, ARMS alveolar rhabdomyosarcoma, ERMS embryonal rhabdomyosarcoma, GU non BP genitourinary non-bladder or prostate, HN non PM head and neck non-parameningeal, GU BP genitourinary bladder or prostate, HN PM Head and neck parameningeal, BM bone-marrow, N0 no clinical or pathological node involvement, N1 clinical or pathological nodal involvement, NX No information on lymph node involvement, HR High Risk, META metastatic, LR Low Risk, SR Standard Risk, NED no evidence of disease, DOD died of disease, AWD alive with disease, a: post-surgical stage according to Intergroup Rhabdomyosarcoma Study (IRS) grouping system41; b: subcutaneous, liver, pancreas, lung, bone-marrow and paravertebral lesion at L2-L3 level; COG, Children’s Oncology Group)

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com